VLS Valneva SE

VALNEVA - Declaration of shares and voting rights: June 30, 2023

VALNEVA - Declaration of shares and voting rights: June 30, 2023

VALNEVA

Declaration of shares and voting rights

June 30, 2023

__________________________________________________________________________________________

Company name: VALNEVA

Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)

Regulated market of Euronext Paris - Compartment B

Declaration date: July 5, 2023

Number of shares

composing the share capital of Valneva
Total number of voting rights including suspended voting rights*Description of the changeDate on which this change was recognizedTotal number of voting rights excluding suspended voting rights**
 



138,896,600



ordinary shares with a par value of €0.15 each





162,164,042Double voting rights granted on 1,151,779 ordinary sharesBetween June 3 & June 30, 2023162,039,720

 __________________________

* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

** Net (or exercisable at a General Meeting) voting rights.

Attachment



EN
05/07/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Valneva SE

Martial Descoutures
  • Martial Descoutures
Damien Choplain ... (+2)
  • Damien Choplain
  • Oscar Haffen Lamm

Valneva : Strong H1 - Key Lyme vaccine catalyst ahead in Q4

Valneva delivered a solid H1 and reaffirmed its 2025 guidance. The company’s cash position, standing at €161m, is sufficient to fund operations through 2027e, providing solid financial visibility. Looking ahead, the next key catalyst is the Phase III data readout for VLA15, Valneva’s Lyme disease v

Martial Descoutures
  • Martial Descoutures

ResearchPool Subscriptions

Get the most out of your insights

Get in touch